Capsugel Hosts International Forum on Innovative Therapeutics in Turkey

October 17, 2017

Experts Explore New Approaches to Improve Dry Powder Inhalation Systems

Morristown, NJ, April 26, 2012– As our population ages and healthcare costs increase, innovative dosage solutions are becoming increasingly important to providing physicians and patients with more cost effective and potentially improved treatment options. International experts in pharmacology, drug development and manufacturing, academia and the public sector gathered in Istanbul today at the 2nd Open Forum on Pharmaceutics and Biopharmaceutics.  Attendees exchanged information about how advancements in dry powder inhalation systems or DPI’s may provide enhancements leading to new innovations and more affordable treatment approaches for physicians and patients in emerging markets and beyond.

“Supergenerics or improved therapeutic entities are an important source for innovation in drug therapy,” said Sven Stegemann, Ph.D., Director for Pharmaceutical Business Development at Capsugel in his opening remarks at the forum.  “Growing demand from emerging markets and ever-increasing pressures on healthcare resources globally amplifies the urgency for establishing efficient technology platforms for DPI development using established regulatory frameworks,” added Dr. Stegemann.
 
Inhalation-based therapy has been widely used to treat chronic respitory conditions such as asthma and Chronic Obstructive Pulmonary Disease (COPD) for many years. Given the direct and fast-acting route of administration as well as the ease of use, there is a growing interest in using inhalation-therapies in other diseases. There are a few different methods for delivering inhalation therapy.  This two-day forum focused on advancements in the use of dry powder inhaler technology.  A white paper highlighting the findings of the 2nd Open Forum on Pharmaceutics and Biopharmaceutics http://www.capsugelopenforums.org/TUFTAD-TR/IstanbulOpenForum/ will be released in the coming months.

“Establishing pharmacokinetic and bioequivalence standards for generic DPI’s is a growing area of interest in Turkey given the advancements in what is currently available and the different diseases this drug delivery method may be able to treat that affect growing populations,” said O.Faruk Bayrakdar, Capsugel’s representative in Turkey. “Capsugel is currently at the forefront of the capsule-based dry powder inhaler market sector – one of the fastest growing drug delivery categories worldwide.”

About Capsugel
Capsugel is a global leader in innovative dosage forms and solutions for the healthcare industry.  Offering a comprehensive array of products and services, from hard gelatin, liquid-filled, and vegetarian capsules, to innovative R&D equipment, Capsugel is at the forefront of drug delivery innovation providing support to customers from formulation to final production.